Long-term statin use does not act on the temporal trend of CD4 cell count in patients on virologically effective HAART

AIDS

Volumn 20, Issue 3, 2006, Pages 455-457

  Manfredi, Roberto ^a   Calza, Leonardo ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BEZAFIBRATE; CD4 ANTIGEN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; ARTICLE; CELL COUNT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DYSLIPIDEMIA; EXERCISE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LABORATORY TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DYSLIPIDEMIAS; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONG-TERM CARE; PROSPECTIVE STUDIES;

EID: 33645036717     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000199822.49488.50     Document Type: Article

References (13)

1. Calza L, Manfredi R, Colangeli V, Tampellini L, Sebastiani T, Pocaterra D, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidemia. AIDS 2005; 19:1051-1058.
2. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005; 118 (Suppl. 2):23S-28S.
3. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45:89-118.
4. Arnaud C, Veillard NR, Mach F. Cholesterol-indipendent effects of statins in inflammation, immunomodulation and atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5:127-134.
5. Corrales-Medina VF, Del Carpio F, Concha R, Symes S. Statin and HIV: beyond the metabolic and cardiovascular benefit. J Acquir Immune Defic Syndr 2005; 39:503-504.
6. Narayan S, Hawley N, Giguere P, Badley AD. Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors. HIV Clin Trials 2003; 4:164-169.
7. Del Real G, Jimènez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004; 200:541-547.
8. Waters L, Stebbing J, Jones R, Mandalia S, Bower M. The effect of statins on HIV rebound and blips. J Acquir Immune Defic Syndr 2005; 39:637-638.
9. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS clinical trials group 5108 study. J Acquir Immune Defic Syndr 2005; 39:307-312.
10. Tsimihodimoas V, Miltiadous G, Daskalopoulou SS, Mikhailidis DP, Elisaf MS. Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol 2005; 3:87-98.
11. Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002; 90:703-710.
12. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, et al. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol 2004; 172:5790-5798.
13. Shafiq N, Malhotra S, Pandhi P, Grover A. The "Statinth" wonder of the world: a panacea for all illnessess or a bubble about to burst. J Negat Results Biomed 2005; 4:3.